Literature DB >> 26454504

Design, synthesis, biological evaluation and docking study of 4-isochromanone hybrids bearing N-benzyl pyridinium moiety as dual binding site acetylcholinesterase inhibitors.

Chaolei Wang1, Zheng Wu1, Hao Cai1, Shengtao Xu1, Jie Liu2, Jieyun Jiang3, Hequan Yao1, Xiaoming Wu1, Jinyi Xu4.   

Abstract

A series of novel 4-isochromanone hybrids bearing N-benzyl pyridinium moiety as dual binding site acetylcholinesterase inhibitors have been designed and synthesized. The screening results showed that most of the compounds exhibited potent anti-AChE activity in the range of nM concentrations. The 1-(4-fluorobenzyl) substituted derivative 9d exhibited the most potent anti-AChE activity with IC50 value of 8.9 nM and high AChE/BuChE selectivity (SI>230). Kinetic and molecular modeling studies suggested that compound 9d was mixed-type inhibitor, binding simultaneously to CAS and PAS of AChE. Besides, the preliminary structure-activity relationships were discussed.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  4-Isochromanone; Acetylcholinesterase; Alzheimer’s disease; Dual binding site; Hybrids

Mesh:

Substances:

Year:  2015        PMID: 26454504     DOI: 10.1016/j.bmcl.2015.09.063

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  8 in total

1.  Novel and Potent Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease from Natural (±)-7,8-Dihydroxy-3-methyl-isochroman-4-one.

Authors:  Xinnan Li; Yilin Jia; Junda Li; Pengfei Zhang; Tiantian Li; Li Lu; Hequan Yao; Jie Liu; Zheying Zhu; Jinyi Xu
Journal:  Molecules       Date:  2022-05-11       Impact factor: 4.927

Review 2.  Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer's disease.

Authors:  Pritam Thapa; Sunil P Upadhyay; William Z Suo; Vikas Singh; Prajwal Gurung; Eung Seok Lee; Ram Sharma; Mukut Sharma
Journal:  Bioorg Chem       Date:  2021-01-29       Impact factor: 5.307

3.  Design, synthesis and evaluation of novel cinnamic acid derivatives bearing N-benzyl pyridinium moiety as multifunctional cholinesterase inhibitors for Alzheimer's disease.

Authors:  Jin-Shuai Lan; Jian-Wei Hou; Yun Liu; Yue Ding; Yong Zhang; Ling Li; Tong Zhang
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

4.  Design, synthesis and biological assessment of new 1-benzyl-4-((4-oxoquinazolin-3(4H)-yl)methyl) pyridin-1-ium derivatives (BOPs) as potential dual inhibitors of acetylcholinesterase and butyrylcholinesterase.

Authors:  Samaneh Zarei; Mohammad Shafiei; Maryam Firouzi; Loghman Firoozpour; Kouros Divsalar; Ali Asadipour; Tahmineh Akbarzadeh; Alireza Foroumadi
Journal:  Heliyon       Date:  2021-04-08

5.  Design, synthesis, and bio-evaluation of new isoindoline-1,3-dione derivatives as possible inhibitors of acetylcholinesterase.

Authors:  Motahareh Hassanzadeh; Farshid Hassanzadeh; Ghadam Ali Khodarahmi; Mahbobe Rostami; Fateme Azimi; Hamid Nadri; Farshad Homayouni Moghadam
Journal:  Res Pharm Sci       Date:  2021-08-19

Review 6.  Recent developments in the design and synthesis of benzylpyridinium salts: Mimicking donepezil hydrochloride in the treatment of Alzheimer's disease.

Authors:  Saghi Sepehri; Mina Saeedi; Bagher Larijani; Mohammad Mahdavi
Journal:  Front Chem       Date:  2022-09-26       Impact factor: 5.545

7.  Novel Acetylcholinesterase Inhibitors Based on Uracil Moiety for Possible Treatment of Alzheimer Disease.

Authors:  Vyacheslav E Semenov; Irina V Zueva; Marat A Mukhamedyarov; Sofya V Lushchekina; Elena O Petukhova; Lilya M Gubaidullina; Evgeniya S Krylova; Lilya F Saifina; Oksana A Lenina; Konstantin A Petrov
Journal:  Molecules       Date:  2020-09-12       Impact factor: 4.411

8.  In vivo Evaluation of a Newly Synthesized Acetylcholinesterase Inhibitor in a Transgenic Drosophila Model of Alzheimer's Disease.

Authors:  Giuseppe Uras; Alessia Manca; Pengfei Zhang; Zsuzsa Markus; Natalie Mack; Stephanie Allen; Marco Bo; Shengtao Xu; Jinyi Xu; Marios Georgiou; Zheying Zhu
Journal:  Front Neurosci       Date:  2021-06-30       Impact factor: 4.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.